| Philip Cohen, | |
|
3800 Reservoir Rd Nw, Washington, DC 20007-2113 | |
| (202) 444-8830 | |
| Not Available |
| Full Name | Philip Cohen |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 3800 Reservoir Rd Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033117197 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 7600 (District Of Columbia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Philip Cohen, Po Box 631856, Baltimore, MD 21263-1856 Ph: () - | Philip Cohen, 3800 Reservoir Rd Nw, Washington, DC 20007-2113 Ph: (202) 444-8830 |
News Archive
Merck & Co., Inc., Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme Limited, announced today that the European Medicines Agency (EMEA) accepted for review the Company's Marketing Authorisation Application (MAA) for regulatory approval of vernakalant intravenous (IV).
Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD916, a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy.
ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QK(e) instrumentation system. The new system, the next generation of the company's initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Additionally, the Octet QK(e) system enables biosensors to be re-racked, for increased workflow flexibility and cost savings.
Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
› Verified 9 days ago
Dr. Adefolaju Oketokun, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1629 K Street Nw, Suite 300, Washington, DC 20006 Phone: 202-636-1360 Fax: 202-636-5137 | |
Dr. Uzoamaka Theodora Nwaogwugwu, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2041 Georgia Avenue Nw, Washington, DC 20060 Phone: 202-865-7677 | |
Ms. Sruthi Nukalapati Reddy, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Road Nw, 6 Phc, Washington, DC 20007 Phone: 202-444-8123 | |
Dr. Kaustubh Subhash Yadwadkar, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Cg201, Washington, DC 20007 Phone: 304-206-7595 | |
Dr. Monica Vohra, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1525 7th St Nw, Washington, DC 20001 Phone: 202-386-7020 Fax: 202-265-1970 | |
Anteneh A Tesfaye, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw Ste C2151, Washington, DC 20010 Phone: 202-877-6998 Fax: 202-877-8909 | |
Erica Nakajima, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5255 Loughboro Rd Nw Fl 1, Washington, DC 20016 Phone: 202-660-6500 |